Virus Safety for Biotherapeutics: Testing and Clearance Strategies Following the ICH Q5A Revision
Planova S20N evaluation on PCC and IgG products
Addressing Continuous Bioprocessing Challenges From Virus Removal Perspective
New Generation Planova™ S20N Demonstrates Robust Performance for Multi-Specific Antibodies
Nanofiltration Strategies in Plasma Protein Process Development
プラノバBioEX: 最小限のリソースで、効率的なウイルスろ過プロセス開発
プラノバBioEX: ウイルスろ過プロセスに関する製造上の検討事項